Chordia Therapeutics Inc. ((JP:190A)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chordia Therapeutics Inc. is conducting a Phase 1/2 multicenter, open-label study titled ‘Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients With Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes.’ The study aims to evaluate the safety, tolerability, and efficacy of CTX-712 in patients with relapsed/refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS). This research is significant as it targets a challenging patient population with limited treatment options.
The intervention being tested is CTX-712, an experimental drug administered orally in tablet form. The purpose of CTX-712 is to provide a new treatment option for patients with relapsed or refractory AML and HR-MDS.
The study design is interventional, non-randomized, and sequential, focusing on treatment. It involves dose escalation to determine the recommended phase 2 dose, followed by expansion cohorts to confirm the dose’s efficacy and safety. No masking is involved, meaning all participants and researchers know the treatment being administered.
The study began on January 24, 2023, with primary completion expected in 2025. The last update was submitted on September 17, 2025. These dates are crucial as they indicate the study’s progression and timeline for potential results.
This clinical study update could influence Chordia Therapeutics’ stock performance positively if the results show promise, as it addresses a critical need in the treatment of AML and HR-MDS. Investors may view this as a potential growth opportunity, especially if CTX-712 proves effective. The competitive landscape includes other companies developing treatments for similar conditions, which could impact market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.